According to Exelixis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 84.2217. At the end of 2022 the company had a P/E ratio of 28.1.
Year | P/E ratio | Change |
---|---|---|
2022 | 28.1 | 13.92% |
2021 | 24.7 | -54.46% |
2020 | 54.2 | 226.32% |
2019 | 16.6 | 94.37% |
2018 | 8.55 | -85.09% |
2017 | 57.4 | -226.95% |
2016 | -45.2 | 540.88% |
2015 | -7.05 | 580.52% |
2014 | -1.04 | -77.69% |
2013 | -4.64 | -6.51% |
2012 | -4.97 | -158.69% |
2011 | 8.46 | -187.63% |
2010 | -9.66 | 65.13% |
2009 | -5.85 | 78.27% |
2008 | -3.28 | -66.92% |
2007 | -9.92 | 28.95% |
2006 | -7.69 | -11.81% |
2005 | -8.72 | 73.53% |
2004 | -5.03 | 3.38% |
2003 | -4.86 | -7.01% |
2002 | -5.23 | -51.55% |
2001 | -10.8 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 11.2 | -86.68% | ๐บ๐ธ USA |
Pfizer PFE | 14.9 | -82.27% | ๐บ๐ธ USA |
Amgen AMGN | 20.2 | -75.98% | ๐บ๐ธ USA |
Sanofi SNY | 15.6 | -81.50% | ๐ซ๐ท France |
Merck MRK | 72.3 | -14.13% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 13.4 | -84.07% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 12.3 | -85.42% | ๐ฌ๐ง UK |
Curis CRIS | -1.09 | -101.29% | ๐บ๐ธ USA |
AVEO Oncology
AVEO | -17.9 | -121.20% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.